Nucleic acid‐based therapeutics that regulate gene expression have been developed
towards clinical use at a steady pace for several decades, but in recent years the field has …

Current research into the role of engineered nanoparticles in drug delivery systems (DDSs)
for medical purposes has developed numerous fascinating nanocarriers. This paper reviews …

Over the past decade, peptide drug discovery has experienced a revival of interest and
scientific momentum, as the pharmaceutical industry has come to appreciate the role that …

The intracellular environment hosts a large number of cancer-and other disease-relevant
human proteins. Targeting these with internalized antibodies would allow therapeutic …

Bone metastasis, a clinical complication of patients with advanced breast cancer, seriously
reduces the quality of life. To avoid destruction of the bone matrix, current treatments focus …

Emerging two-dimensional (2D) nanomaterials, such as transition-metal dichalcogenide
(TMD) nanosheets (NSs), have shown tremendous potential for use in a wide variety of …

Oligonucleotide-based drugs have received considerable attention for their capacity to
modulate gene expression very specifically and as a consequence they have found …

Nucleic acids and their synthetic oligonucleotide (ON) analogs are a group of gene
therapeutic compounds which hold enormous clinical potential. Despite their undoubted …

Cell-penetrating peptides (CPPs) are naturally able to cross the lipid bilayer membrane that
protects cells. These peptides share common structural and physicochemical properties and …

Cell-penetrating peptides (CPP) are promising tools for the transport of a broad range of
compounds into cells. Since the discovery of the first members of this peptide family, many …